Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirogabalin in DPNP or PHN with Renal Impairment (Japan, Phase 3, Open-label, 14-week)
jRCT2080223005Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of mirogabalin in diabetic polyneuropathy (DPN) and postherpetic neuralgia (PHN) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety and tolerability of mirogabalin. Started Nov 2015; status: completed.
02
Drugs
mirogabalin
03
Conditions
diabetic polyneuropathy (DPN)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on jRCT2080223005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223005.